A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Public ClinicalTrials.gov record NCT07365319. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
Study identification
- NCT ID
- NCT07365319
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 750 participants
Conditions and interventions
Interventions
- EIK1001 Drug
- Pembrolizumab (KEYTRUDA®) Drug
- Placebo Drug
- Paclitaxel + Carboplatin Drug
- Nab-paclitaxel + Carboplatin Drug
- Pemetrexed + Cisplatin /Carboplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 14, 2026
- Primary completion
- Dec 30, 2035
- Completion
- Dec 30, 2040
- Last update posted
- Sep 1, 2026
2026 – 2040
United States locations
- U.S. sites
- 16
- U.S. states
- 9
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center, P.C. | Daphne | Alabama | 36526 | Recruiting |
| Los Angeles Cancer Network | Glendale | California | 91204 | Recruiting |
| Providence St. Joseph Hospital | Orange | California | 92868 | Recruiting |
| Rocky Mountain Cancer Centers, LLP | Pueblo | Colorado | 81103 | Recruiting |
| Florida Clinical Trials Group | Plantation | Florida | 33322 | Recruiting |
| Florida Clinical Trials Group - Tamarac | Tamarac | Florida | 33321 | Recruiting |
| OSF Saint Francis Medical Center | Peoria | Illinois | 61637 | Recruiting |
| University of New Mexico - Comprehensive Cancer Center | Albuquerque | New Mexico | 87102 | Recruiting |
| NYU Langone Hospital Long Island | Mineola | New York | 11501 | Recruiting |
| NYU Langone Hospital Manhattan | New York | New York | 10016 | Recruiting |
| Jacobi Medical Center - Albert Einstein College of Medicine | The Bronx | New York | 10461 | Recruiting |
| White Plains Hospital | White Plains | New York | 10601 | Recruiting |
| Tennessee Oncology | Nashville | Tennessee | 37203 | Recruiting |
| Blue Ridge Cancer Center | Blacksburg | Virginia | 24060 | Recruiting |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | Recruiting |
| Shenandoah Oncology P.C. | Winchester | Virginia | 22601 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07365319, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 1, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07365319 live on ClinicalTrials.gov.